Privia Health Group (PRVA) Projected to Post Quarterly Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $494.9840 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Tuesday, June 7th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $213.61 million for the quarter. Privia Health Group had a return on equity of 2.13% and a net margin of 0.78%. On average, analysts expect Privia Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Privia Health Group Stock Up 1.9%

PRVA stock opened at $24.76 on Tuesday. The company has a market cap of $3.04 billion, a PE ratio of 225.11, a price-to-earnings-growth ratio of 3.31 and a beta of 0.83. Privia Health Group has a 52 week low of $18.50 and a 52 week high of $26.49. The business has a 50-day simple moving average of $23.96 and a 200 day simple moving average of $22.73.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Zacks Research raised shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Evercore ISI reduced their target price on Privia Health Group from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, July 9th. Stephens reiterated an “overweight” rating and issued a $32.00 price target on shares of Privia Health Group in a research note on Wednesday, September 24th. Citigroup restated an “outperform” rating on shares of Privia Health Group in a research report on Friday, August 29th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Privia Health Group in a research note on Wednesday, October 8th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and a consensus target price of $28.91.

Institutional Trading of Privia Health Group

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. acquired a new stake in Privia Health Group during the 2nd quarter worth approximately $1,819,000. California State Teachers Retirement System lifted its holdings in shares of Privia Health Group by 1.6% during the second quarter. California State Teachers Retirement System now owns 89,631 shares of the company’s stock worth $2,062,000 after purchasing an additional 1,405 shares during the period. Occudo Quantitative Strategies LP acquired a new position in shares of Privia Health Group during the second quarter worth $691,000. The Manufacturers Life Insurance Company grew its stake in shares of Privia Health Group by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 59,101 shares of the company’s stock worth $1,359,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Norges Bank acquired a new stake in Privia Health Group in the second quarter valued at $728,000. 94.48% of the stock is currently owned by institutional investors.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.